# Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

> **NCT06014255** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 219 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enoblituzumab
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT06014255
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-16
- **Primary completion:** 2029-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 219 (ESTIMATED)
- **Last updated:** 2025-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014255, "Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06014255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*